RESEARCHERS! SAVE TIME & MONEY ON YOUR NEXT NEXT GENERATION SEQUENCING PROJECT!
The Genohub next generation sequencing market opens today to a number of researchers who could benefit from placing their next-gen sequencing order through Genohub. If you would like to take part in our initial launch please visit our shopping page, enter a few bits of information such as the number of samples to sequence and minimum number of reads, or coverage per sample, and we will instantly match you with the best providers for your project. You also have the ability to search by specific technology if you require a service provider with specific platforms and library types. It is 100% free to search and place an order, and we are currently offering free consultation from our science staff.
Here are some of the other ways we help researchers on Genohub:
Save time shopping for the best price on costly sequencing projects
Eliminate the need for researching the technologies in order to find suitable sequencing solutions
Offer more predictability on turnaround time and quality
Centralized per-project communication platform
Of course we realize that you have a number of options available when it comes to finding the best next generation sequencing provider for your project. In fact, we developed Genohub to help researchers in ways that have not been available up until now. Genohub is unique in that we offer:
Structured service listings
Intelligent technology-aware software that automatically matches project requirements with providers’ service listings
Shopping, ordering and project management process tailored to sequencing projects
As a researcher, we encourage you to visit our shopping page and let us know what you think! And of course if you need any assistance along the way, we would be more than glad to help.
If you get the inkling to know just where high throughput sequencing providers and sequencers themselves are located worldwide, there’s an excellent resource to help you do just that. If you haven’t come across this yet, Omicspaps.com is a crowd-sourced map which not only lists service providers globally, but also allows users to view the locations of selected individual sequencers. The site is aptly titled “Next Generation Genomics: World Map of High-Throughput Sequencers”. The home page is comprised of a map built on a Google Maps foundation that overlays the locations of sequencing providers and sequencers. Below is a screenshot of this view:
Omicsmaps – High Throughput Sequencing Locations
Users also have the option to filter by country. What is also quite interesting is the “Machine Statistics” link on the top right hand corner of the main screen which upon clicking, displays the total numbers of facilities per country, sequencers per provider, and many other interesting factoids. Here are a few highlights:
- Largest genome center in the US: the Broad Institute of MIT and Harvard takes the cake on this one with a whopping 101 sequencing machines
- The #1 high throughput sequencing platform in use today: this badge belongs to the Illumina HiSeq 2000 with 739 machines globally
- There are more sequencing machines in the US than the next lower 6 countries on this list combined!
Each high throughput sequencing service provider also includes a link to their website which some might find useful. Another great way to get in touch with sequencing providers is through the Genohub shopping interface. Some of the best sequencing providers have already signed up with Genohub to also list their equipment along with the associated services, pricing, and additional value they offer. We encourage you to give it a try!
The next generation sequencing market is poised to reach $2.7 billion by 2017 as presented by marketsandmarkets.com. This represents an estimated growth of 16.3% from a market value of $1.3 billion in 2012. Marketsandmarkets presents a detailed analysis of their findings from which the following top next generation sequencing market drivers and hindrances are derived:
5 Top NGS Market Drivers:
- Continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs
- Improved turnaround time
- Government funding
- Increasing opportunities in NGS clinical applications
- Presence of dominant NGS platform players
Although the next generation sequencing market is growing rapidly, there are factors which have been weighing down the market as a whole.
5 Top NGS Market Hindrances:
- High reliability on grants and funding from the government
- Decrease in capital expenditure from academic institutions
- Accuracy and standardization concerns
- Data storage problems
- Issues in interpretation of complex data
The future of the NGS market promises to offer a simpler, less costly, and more integrated experience for researchers. The market is also poised to revolutionize applied markets like diagnostics, drug discovery, biomarker discovery, personalized medicine, and agriculture and animals research.
Illumina presented at the Goldman Sachs 34th Annual Global Healthcare Conference June 12th, 2013. Here are the highlights on the future direction of Illumina, as stated by CEO Jason Flatley. For the entire unabridged version, please visit www.seekingalpha.com.
- On future product requirements: “Well, it certainly needs to be very easy to use. It needs to be deployable, probably on multiple platforms so that you can address both the centralized lab requirements in some geographies but also the more fragmented labs in other geographies…It needs to be a product that has very automated software associated with it and ultimately, one that could be sold into the hospital setting.”
- On the direction of BaseSpace: “BaseSpace is strategically very important for us, not only the ability to create this initial killer app in data sharing but in the long run, the whole idea of the App Store and the ability to sort of capture the customer imagination and have one single place where customers can go to run a broad suite of different applications, whether they come from us or from other software suppliers. And that will create a level of convenience for our customers, I think, that will be unprecedented.”
- On whether the future is in gene panels or whole genome: “Well, we think there’s going to be a market for both for some time, but we think the world will move to full genome sequencing as prices continue to come down. There’s really 2 reasons why people might not do that today and certainly, price is one of them. The second certainly has to do with sort of discoveries that are unintended, so unreportable results. And what you do is discoveries that happen that were not in parts of the genes that you cared about. And that’s a big concern for people in the ethical side about what you do with those pieces of data.”
- On third generation technologies: “We think they’re still ways away from the market. It’s a very difficult — particularly nanopore is a very difficult technology to get to work robustly. And I think that’s been shown by how long it’s taken Oxford to get their products into the marketplace. And certainly, we’re making great progress in our labs, but we think it’s some years away from being commercially available.”
- On sample prep: “We think there’s a tremendous amount of additional work we can do to improve the technology in Sample Prep to make it simpler for our customers, more automated, more LIMS enabled. And I’d say we’re just really getting started in the Sample Prep around, if you fast-forward 3 to 5 years, you’re going to see sequencing be much more integrated operationally than what you see today.”
The overarching theme in this transcript in full is that Illumina next generation sequencing should become more automated and focused around providing customers with a more simple, integrated experience.
We want to welcome Longhorn Vaccines and Diagnostics to the Genohub family. The high throughput sequencing services listed by Longhorn will add more available options to the Genohub next generation sequencing market.
Longhorn Vaccines added the following instruments and library prep options:
- Instruments: Ion PGM 314 Chip, and Ion PGM 318 Chip
- Library prep: Ion Amplicon, and Ion total RNA
We look forward to matching Longhorn Vaccines with the most compatible high throughput sequencing orders for their lab.
Dr Luke Daum and team at Longhorn Diagnostics also provided us with some excellent feedback on the Genohub platform. At Genohub we strive to maintain a close ear to our clients and continue to improve the experience and service we provide based directly on feedback. We look forward to incorporating suggestions by the Longhorn team into future Genohub iterations.